Related Experiment Videos
UFT-induced haemolytic anaemia.
Cancer Chemotherapy and Pharmacology
|April 26, 2001
Summary
A patient developed haemolytic anaemia while undergoing treatment for metastatic colon cancer with UFT (uracil and tegafur). This is the first reported case linking UFT, an oral chemotherapy, to this adverse effect.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Metastatic colon cancer requires effective chemotherapeutic agents.
- UFT (uracil and tegafur) is an oral chemotherapy used for colon cancer.
- Haemolytic anaemia is a known side effect of various chemotherapeutic agents.
Observation:
- A patient with metastatic colon cancer developed haemolytic anaemia.
- The patient was undergoing treatment with UFT.
Findings:
- This case represents the first documented instance of haemolytic anaemia associated with UFT.
- UFT, an oral anticancer drug, combines tegafur (a 5-fluorouracil prodrug) and uracil.
Implications:
- Clinicians should be aware of the potential for UFT to cause haemolytic anaemia.
- Further investigation into the mechanism of UFT-induced haemolytic anaemia is warranted.
- Monitoring for haematological adverse events is crucial in patients receiving UFT.